Ligand Pharmaceuticals Incorporated Stock Price on November 6, 2024
| LGND Stock | USD 118.60 2.26 1.94% |
Below is the normalized historical share price chart for Ligand Pharmaceuticals Incorporated extending back to November 18, 1992. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Ligand Pharmaceuticals stands at 118.60, as last reported on the 11th of December 2024, with the highest price reaching 119.70 and the lowest price hitting 114.00 during the day.
If you're considering investing in Ligand Stock, it is important to understand the factors that can impact its price. Ligand Pharmaceuticals appears to be very steady, given 3 months investment horizon. Ligand Pharmaceuticals has Sharpe Ratio of 0.0979, which conveys that the firm had a 0.0979% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Ligand Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please exercise Ligand Pharmaceuticals' Risk Adjusted Performance of 0.0737, mean deviation of 1.93, and Downside Deviation of 2.95 to check out if our risk estimates are consistent with your expectations.
The current year's Total Stockholder Equity is expected to grow to about 736 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 16.2 M. . The current year's Price Earnings Ratio is expected to grow to 24.87, whereas Price To Sales Ratio is forecasted to decline to 9.20. Ligand Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 18th of November 1992 | 200 Day MA 93.7561 | 50 Day MA 112.3222 | Beta 0.896 |
Ligand |
Sharpe Ratio = 0.0979
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LGND | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.83 actual daily | 25 75% of assets are more volatile |
Expected Return
| 0.28 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Ligand Pharmaceuticals is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ligand Pharmaceuticals by adding it to a well-diversified portfolio.
Price Book 2.6133 | Enterprise Value Ebitda 20.7415 | Price Sales 14.7026 | Shares Float 18.5 M | Wall Street Target Price 140.375 |
Related Headline
Apellis Pharmaceuticals Headline on 6th of November 2024
Needham Company LLC Lowers Apellis Pharmaceuticals Price Tar... by thelincolnianonline.com
Apellis Pharmaceuticals had its price target cut by analysts at Needham Company LLC from 85.00 to 60.00 in a report released on Wednesday, Benzinga reports. The firm currently has a buy rating on the stock. Needham Company LLCs price objective indicates a potential upside of 113.71 percent from the
Ligand Pharmaceuticals Valuation on November 6, 2024
It is possible to determine the worth of Ligand Pharmaceuticals on a given historical date. On November 6, 2024 Ligand was worth 114.09 at the beginning of the trading date compared to the closed value of 116.9. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Ligand Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Ligand Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Ligand Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Ligand Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 109.57 | 111.59 | 108.31 | 111.13 | 82,981 | |
11/06/2024 | 114.09 | 116.95 | 111.81 | 116.90 | 214,603 |
| 118.33 | 129.90 | 115.16 | 129.90 | 271,689 |
| Backtest Ligand Pharmaceuticals | | | Ligand Pharmaceuticals History | | | Ligand Pharmaceuticals Valuation | Previous | Next |
Ligand Pharmaceuticals Trading Date Momentum on November 6, 2024
| On November 07 2024 Ligand Pharmaceuticals Incorporated was traded for 129.90 at the closing time. The top price for the day was 129.90 and the lowest listed price was 115.16 . The trading volume for the day was 271.7 K. The trading history from November 7, 2024 was a factor to the next trading day price growth. The trading delta at closing time against the next closing price was 11.12% . The trading delta at closing time against the current closing price is 5.16% . |
Ligand Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Ligand Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Ligand Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Ligand financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Ligand Pharmaceuticals Stock history
Ligand Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Ligand is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Ligand Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Ligand Pharmaceuticals stock prices may prove useful in developing a viable investing in Ligand Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 17.8 M | 16.2 M | |
| Net Loss | -38.4 M | -36.4 M |
Ligand Pharmaceuticals Quarterly Net Working Capital |
|
Ligand Pharmaceuticals Stock Technical Analysis
Ligand Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Ligand Pharmaceuticals Period Price Range
Low | December 11, 2024
| High |
0.00 | 0.00 |
Ligand Pharmaceuticals Incorporated cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Ligand Pharmaceuticals December 11, 2024 Market Strength
Market strength indicators help investors to evaluate how Ligand Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Ligand Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Ligand Pharmaceuticals stock market strength indicators, traders can identify Ligand Pharmaceuticals Incorporated entry and exit signals to maximize returns
Ligand Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Ligand Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Ligand Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Ligand to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0737 | |||
| Jensen Alpha | 0.0834 | |||
| Total Risk Alpha | (0.19) | |||
| Sortino Ratio | 0.0441 | |||
| Treynor Ratio | 0.1736 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Ligand Stock analysis
When running Ligand Pharmaceuticals' price analysis, check to measure Ligand Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ligand Pharmaceuticals is operating at the current time. Most of Ligand Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ligand Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ligand Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ligand Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |